Trarbach, T <br/><br/>
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.  [electronic resource] 

 -  British journal of cancer  Feb 2010 
 - 506-12 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/sj.bjc.6605507  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Colorectal Neoplasms--drug therapy<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>Male<br/>Middle Aged<br/>Receptors, TNF-Related Apoptosis-Inducing Ligand--agonists